Ultragenyx Pharmaceutical Inc $RARE
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-37
RECRUITING2
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO75%
Delay Index: of 8 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +19.0 months). See all sponsors →
Open Ultragenyx Pharmaceutical Inc on the live radar map → 📅 $RARE readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Orbit NCT05125809 |
P2/3 | Active, not recruiting | Osteogenesis Imperfecta | 183 | 2025-10-20 (+8 mo) |
| Cosmic NCT05768854 |
P3 | Active, not recruiting | Osteogenesis Imperfecta | 69 | 2025-10-23 (-1 mo) |
| setrusumab NCT06636071 |
P3 | Active, not recruiting | Osteogenesis Imperfecta | 6 | 2027-01 |
| Triheptanoin NCT05933200 |
P3 | Active, not recruiting | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | 69 | 2027-08 (+11 mo) |
| No Investigational Product NCT04360265 |
P3 | Enrolling by invitation | Mucopolysaccharidosis IIIA; MPS IIIA | 41 | 2027-08 (+19 mo) |
| DTX301 NCT05345171 |
P3 | Active, not recruiting | OTC Deficiency | 37 | 2027-09 (+33 mo) |
| UX016 NCT07511556 |
P1/2 | Recruiting | GNE Myopathy | 24 | 2028-12 |
| UX701 NCT04884815 |
P1/2 | Active, not recruiting | Wilson Disease | 82 | 2029-03 (+27 mo) |
| UX111 NCT02716246 |
P2/3 | Recruiting | MPS IIIA; Sanfilippo Syndrome | 36 | 2029-03 (+111 mo) |